© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
Investors cannot turn a blind eye to insiders as well as institutional ownership. They need to follow insider trades to determine the direction the stock is likely to take.
About 51.61% of ABUS shares are held by financial institutions. JPMORGAN CHASE & CO is the top corporate investor, holding 88.13K shares valued at $227.38K. A 0.05% stake in Arbutus Biopharma Corporation is owned by the company. BARCLAYS PLC owns 89.19K shares valued at $230.00K, which translates its holding of 0.05% of the stake in the company.
Among the ABUS insiders holding of 22.3% of the stake in company, MCELHAUGH MICHAEL J., Interim President & CEO, holds the largest shares of 1.5M. SOFIA MICHAEL J., Chief Scientific Officer, is the second largest ABUS insider with ownership of 1.49M shares. MACHADO PATRICK, 10 percent owner, stands third with possession of 1.16M shares of that stake.
A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own ABUS shares is 178, representing 51.61% of the company's common stock.
JPMORGAN CHASE & CO, in the last quarter, reduced its stake in ABUS by -23.68% restricting it's holding to 88.13 thousand shares of worth nearly $227.38K. BARCLAYS PLC also lessened -58.7% of the ABUS shares from its portfolio, reducing its holding to 89.19 thousand shares of worth $230.00K. UBS GROUP AG also shunned ABUS shares holding by -3.68% last quarter which brought its holding to 134.82 thousand shares worth $347.84K.
As per its latest 13F filing, AMERICAN CENTURY COMPANIES INC increased its stake in ABUS by 53.17% in the last quarter. The institutional holder raised its holding to 126.21 thousand shares having worth more than $325.63K. FMR LLC also added 0.3% more shares of ABUS to its portfolio, raising its holding to 165.84 thousand shares of worth $427.87K. RHUMBLINE ADVISERS also increased its ABUS shares holding by 3.55% which brought its holding to 170.46 thousand shares worth $439.78K.
The insider with the most stakes in ABUS is McElhaugh Michael J. , Interim President & CEO at the company. Additionally, ABUS stock is highly held by Chief Scientific Officer Sofia Michael J. and 10 percent owner Machado Patrick among others.
Company executives, directors, and other insiders own 22.3% percent of Arbutus Biopharma Corporation's stock. Within the last six months, there have been 1 transaction(s) in which ABUS insiders have sold stock, totaling 8.85K shares. Insiders that have sold shares include MANCHESTER KEITH S, SIMS KAREN, and HASTINGS DAVID C.
There have been 0 transaction(s) during the past 6-months in which Arbutus Biopharma Corporation insiders have bought stock, totalling 0 shares
Around 46.07K Arbutus Biopharma Corporation shares are held by insiders, which represents about 22.3% of ABUS stock.
ABUS Interim President & CEO, McElhaugh Michael J. holds the largest portfolio of the company's shares. ABUS shares owned by McElhaugh total nearly 1.5 million.
JPMORGAN CHASE & CO is the largest institutional owner in ABUS which holds 88.13 thousand shares worth $227.38K or 0.05% of the total ABUS shares outstanding followed by BARCLAYS PLC with ownership of 89.19 thousand shares representing 0.05% of the ABUS ownership. AMERICAN CENTURY COMPANIES INC is the third largest stakeholder with 126.21 thousand shares or 0.08% of the ownership worth more than $325.63K.
Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the ABUS is concerned, it is a stock which is optionable.
Number of ABUS shares short is 7.79M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.
As of today, 188.78M shares of ABUS are outstanding.
Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, ABUS has 135.51M shares in float.
Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for ABUS is 6.52.